Otros idiomas Shuttle Pharmaceuticals Holdings, Inc.

Acciones

SHPH

US8256932034

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 28/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,4438 ^USD	+6,97 %		+6,79 %	-2,46 %

21/03	Shuttle Pharmaceuticals Holdings, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
08/01	Shuttle Pharmaceuticals recibe la aprobación de la FDA para proceder con el ensayo clínico de fase II de ropidoxuridina para el tratamiento de pacientes con glioblastoma	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	22/05
Shuttle Pharma Provides First Quarter 2024 Corporate Update	14/05
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	23/04
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024	03/04
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	25/03
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	22/03
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024	05/03
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering	13/02
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.25 million in funding	07/02
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	23/01
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma	08/01
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	12/12
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	11/12
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023	30/11
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update	14/11
Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program through Exclusive License Agreement	01/11
Shuttle Pharmaceuticals : Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement - Form 8-K	30/10/23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference	10/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Shuttle Pharmaceuticals Holdings, Inc.

Acciones

SHPH

US8256932034

Otros idiomas

Filtros